Latest Articles

Publication Date
Construction organoid model of ovarian endometriosis and the function of estrogen and progesterone in the model - Nature.com

Construction organoid model of ovarian endometriosis and the function of estrogen and progesterone in the model Nature.com

Published: Feb. 24, 2025, 5:59 p.m.
Construction organoid model of ovarian endometriosis and the function of estrogen and progesterone in the model.

Endometriosis is a refractory estrogen-dependent gynecological disease in which ovarian endometriosis(OE) is the most common, and the main cell components are endometrial epithelial cells and stromal cells. However, constructing ectopic …

Published: Feb. 24, 2025, midnight
Primary Low-Grade Endometrial Stromal Sarcoma of the Ovary Arising From Endometriosis: A Case Report.

Low-grade endometrial stromal sarcoma (LGESS) is a rare mesenchymal tumor of female genital tract malignancies. While it primarily arises in the uterus, extrauterine cases, including those originating in the ovary, …

Published: Feb. 23, 2025, midnight
Molecular Basis of Impaired Decidualization in the Eutopic Endometrium of Endometriosis Patients.

Endometriosis is a chronic gynecological disorder characterized by the presence of endometrial tissue outside the uterine cavity. A common feature of this pathology is the impaired decidualization of endometrial stromal …

Published: Feb. 21, 2025, midnight
Single-cell transcriptomic atlas of different endometriosis indicating that an interaction between endometriosis-associated mesothelial cells (EAMCs) and ectopic stromal cells may influence progesterone resistance.

Endometriosis is a hormone-dependent disease, which can usually be divided into peritoneal endometriosis (PEM), deep-infiltrating endometriosis (DIE) and ovarian endometriosis (OEM). Although the three pathologic types are essentially the same …

Published: Feb. 20, 2025, 12:34 a.m.
PARP-2 acts on ILK signaling and pharmacological targeting of PARP-2 ameliorate endometriosis in a mouse model.

Endometriosis, an endocrine disorder in reproductive-aged women with an occurrence of ∼10 %, gives rise to inflammation, pelvic pain, menstrual irregularity, infertility, etc. One study demonstrated the elevated plasma level …

Published: Feb. 20, 2025, midnight
The application of progesterone-primed ovarian stimulation protocol in patients with ovarian endometriosis combined with diminished ovarian reserve.

The aim was to investigate the value of the application of a progesterone-primed ovarian stimulation (PPOS) protocol in patients with ovarian endometriosis (OEM) combined with diminished ovarian reserve (DOR).

Published: Feb. 18, 2025, midnight
Comparison of vaginal versus intramuscular progesterone in programmed cycles for frozen-thawed blastocyst transfer in patients with endometriosis.

Previous studies have shown that due to the presence of endometrium progesterone resistance in patients with endometriosis, it is considered that higher levels of progesterone may be required to achieve …

Published: Feb. 6, 2025, midnight
Azurocidin is Associated with Dienogest-resistance in Ovarian Endometriotic Cysts.

Endometriosis and ovarian endometrioma (OMA) cause dysmenorrhea and infertility. Current hormonal therapies for OMA treatment, may exhibit limited effectiveness. Hormonal treatments function by downregulate estrogen receptors (ERs) via progesterone receptor …

Published: Feb. 5, 2025, midnight
Data pharmacovigilance analysis of medroxyprogesterone-related adverse events in the FDA adverse event reporting system.

Medroxyprogesterone acetate (MPA), a steroid progesterone, is widely used to treat endometriosis, menstrual disorders, and uterine bleeding in clinical practice. However, the safety profile of MPA requires comprehensive evaluation.

Published: Jan. 31, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!